文献速递造血干细胞移植与细胞治疗贫血与红细胞疾病

重组人血小板生成素对重型再生障碍性贫血患者异基因造血干细胞移植后血小板恢复的影响

[Impact on platelet recovery of recombinant human thrombopoietin in severe aplastic anemia patients with allogeneic hematopoietic stem cell transplantation].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2018-01-01

该回顾性分析纳入85例接受allo-HSCT的SAA患者,分为rhTPO组29例、rhIL-11组27例和空白组29例。rhTPO组PLT≥100×10⁹/L恢复时间短于rhIL-11组及空白组,血小板输注量少于两组,骨髓巨核细胞计数高于rhIL-11组,应用rhTPO是血小板恢复的独立影响因素。

要点

  • rhTPO组PLT≥100×10⁹/L恢复时间23(12~51)d,短于rhIL-11组28(12~80)d及空白组35(18~86)d。
  • rhTPO组血小板输注量20(10~30)U,少于rhIL-11组30(10~50)U及空白组35(10~70)U。
  • 多因素分析显示应用rhTPO是血小板恢复的独立影响因素,HR=4.01(95%CI 1.81~8.97),P=0.010。

核心结论

  • rhTPO可以促进SAA患者allo-HSCT后血小板恢复、减少血小板输注量,并且安全性较好。

研究设计与样本

  • 回顾性分析2010年1月至2017年3月济南军区总医院血液科85例接受allo-HSCT治疗的SAA患者,按升血小板药物使用分为rhTPO组29例、rhIL-11组27例和空白组29例。

主要发现

  • 三组粒细胞植入和PLT≥20×10⁹/L的中位时间差异均无统计学意义(P>0.05)。
  • rhTPO组PLT≥50×10⁹/L时间短于空白组[16.5(11~39)d对22(14~66)d,P<0.05];rhTPO组PLT≥100×10⁹/L时间23(12~51)d短于rhIL-11组28(12~80)d及空白组35(18~86)d(P<0.05)。
  • rhTPO组移植期间血小板输注量20(10~30)U,少于rhIL-11组30(10~50)U及空白组35(10~70)U(P<0.05)。
  • 移植后(25±5)d骨髓巨核细胞中位计数rhTPO组31.5(0~200)个、rhIL-11组12(0~142)个、空白组11(0~187)个,rhTPO组与rhIL-11组比较差异有统计学意义(P<0.05),rhIL-11组与空白组比较差异无统计学意义(P>0.05)。
  • 多因素分析显示应用rhTPO是影响血小板恢复的独立影响因素[HR=4.01(95%CI 1.81~8.97),P=0.010];rhTPO组未见明显不良反应。

临床怎么用

  • 原文结论为rhTPO可以促进SAA患者allo-HSCT后血小板恢复、减少血小板输注量,并且安全性较好。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate and analyze the impact on PLT recovery of recombinant human thrombopoietin (rhTPO) in severe aplastic anemia (SAA) patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: A retrospective analysis of Hematology Division of General Hospital of Jinan Military Command was conducted in the 85 SAA cases who treated with allo-HSCT from January 2010 to March 2017. According to the administration of medicines for platelets, 85 patients were divided into rhTPO group (n=29), rhIL-11 group (n=27) and blank group (n=29), respectively. The median time of PLT ≥20×109/L, PLT ≥50×109/L, and PLT ≥100×109/L, the numbers of megakaryocytes in marrow smear (25±5) days after transplantation and the quantities of platelet transfusion were analyzed retrospectively. The adverse events of rhTPO and rhIL-11 groups were observed. Results: There were no significant differences in the recovery of granulocytes and PLT ≥20×109/L among the three groups (P>0.05). The time of PLT ≥50×109/L in rhTPO group was shorter than that in blank group [16.5 (11-39) d vs 22 (14-66) d, P<0.05], as well as the time of PLT ≥100×109/L [rhTPO: 23 (12-51) d; rhIL-11: 28 (12-80) d; blank group: 35 (18-86) d, P<0.05]. Platelet transfusions were also less in rhTPO group than in rhIL-11 and blank groups [20 (10-30) U, 30 (10-50) U, 35 (10-70) U, P<0.05]. The counts of megakaryocyte in rhTPO group, rhIL-11 group and blank group were 31.5 (0-200), 12 (0-142) and 11(0-187) (P<0.05), respectively. The difference between rhTPO group and rhIL-11 group was statistically significant (P<0.05), but no difference between rhIL-11 group and blank group (P>0.05). Multivariate analysis showed that rhTPO was an independent factor for platelet recovery [HR=4.01 (95%CI 1.81-9.97), P=0.010]. The rhTPO group had no obvious adverse events. Conclusion: rhTPO can promote platelet recovery of SAA patients after allo-HSCT, reduce platelet transfusion with safety. 目的: 分析重组人血小板生成素(rhTPO)促进重型再生障碍性贫血(SAA)患者异基因造血干细胞移植(allo-HSCT)后血小板恢复的疗效及安全性。 方法: 对2010年1月至2017年3月期间85例接受allo-HSCT治疗的SAA患者进行回顾性分析。根据移植后升血小板药物的使用情况,将85例患者分为rhTPO组(29例)、rhIL-11组(27例)和空白组(29例),比较三组PLT≥20×109/L、PLT≥50×109/L、PLT≥100×109/L的恢复时间以及移植后(25±5)d骨髓巨核细胞计数、移植期间血小板输注量,观察药物不良反应。 结果: rhTPO、rhIL-11、空白组粒细胞植入和PLT≥20×109/L的中位时间差异均无统计学意义(P>0.05)。rhTPO组PLT≥50×109/L时间短于空白组[16.5(11~39)d对22(14~66)d,P<0.05];rhTPO组PLT≥100×109/L时间[23(12~51)d]短于rhIL-11组[28(12~80)d]及空白组[35(18~86)d](P<0.05)。rhTPO组移植期间血小板输注量少于rhIL-11组及空白组[分别为20(10~30)、30(10~50)、35(10~70)U,P<0.05]。rhTPO、rhIL-11、空白组移植后(25±5)d骨髓巨核细胞中位计数分别为31.5(0~200)、12(0~142)、11(0~187)个,rhTPO组与rhIL-11组比较差异有统计学意义(P<0.05),rhIL-11组与空白组比较差异无统计学意义(P>0.05)。多因素分析显示,应用rhTPO是影响血小板恢复的独立影响因素[HR=4.01(95%CI 1.81~8.97),P=0.010]。rhTPO组未见明显不良反应。 结论: rhTPO可以促进SAA患者allo-HSCT后血小板恢复、减少血小板输注量,并且安全性较好。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Song Y, Zhou F, Song NX, et al. [Impact on platelet recovery of recombinant human thrombopoietin in severe aplastic anemia patients with allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 29562465. doi:10.3760/cma.j.issn.0253-2727.2018.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。